Denali Therapeutics (NASDAQ: DNLI) nets $195M in priority review voucher sale
Rhea-AI Filing Summary
Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026. The transaction was carried out under an asset purchase agreement dated June 12, 2026.
Denali received gross proceeds of $195.0 million from the buyer upon closing of the sale. The voucher had been obtained when tividenofusp alfa was approved by the U.S. Food and Drug Administration for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. Denali plans to file the full PRV Transfer Agreement as an exhibit in a subsequent Securities and Exchange Commission filing.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 2.01, 9.01
2 items
Item 2.01
Completion of Acquisition or Disposition of Assets
Financial
The company completed a significant acquisition or sale of business assets.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
PRV sale gross proceeds: $195.0 million
PRV Transfer Agreement date: June 12, 2026
Tividenofusp alfa approval timing: March 2026
3 metrics
PRV sale gross proceeds
$195.0 million
Gross proceeds received upon closing of PRV sale on July 27, 2026
PRV Transfer Agreement date
June 12, 2026
Date of asset purchase agreement governing the PRV sale
Tividenofusp alfa approval timing
March 2026
Month and year FDA approved tividenofusp alfa for Hunter syndrome
Key Terms
Rare Pediatric Disease Priority Review Voucher, asset purchase agreement, tividenofusp alfa
3 terms
Rare Pediatric Disease Priority Review Voucher regulatory
"completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher"
A rare pediatric disease priority review voucher is a transferable regulatory benefit awarded to a company that wins approval for a drug treating a serious but uncommon childhood illness. It works like a “fast-pass” with regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs.
asset purchase agreement financial
"The Sale was completed pursuant to the terms of an asset purchase agreement"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
tividenofusp alfa medical
"The Company received the PRV when (tividenofusp alfa) was approved"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Denali Therapeutics (DNLI) report in this Form 8-K?
Denali Therapeutics reported completing the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company on July 27, 2026, under an asset purchase agreement dated June 12, 2026, for cash proceeds at closing.
How much did Denali Therapeutics (DNLI) receive from selling its PRV?
Denali received gross proceeds of $195.0 million from the buyer upon closing of the PRV sale. This amount was paid at closing under the PRV Transfer Agreement described in the report.
When and how did Denali Therapeutics (DNLI) obtain its Rare Pediatric Disease PRV?
Denali obtained the Rare Pediatric Disease Priority Review Voucher when tividenofusp alfa was approved by the U.S. Food and Drug Administration in March 2026 for treating Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II).
Who purchased Denali Therapeutics’ (DNLI) Rare Pediatric Disease PRV and when did the sale close?
The PRV was sold to a large pharmaceutical company, which is not named in the report. The sale closed on July 27, 2026, when Denali received the agreed gross proceeds.
Will Denali Therapeutics (DNLI) disclose the full PRV Transfer Agreement terms?
Denali states that the description of the PRV Transfer Agreement is summary only and that the full agreement will be filed as an exhibit to a subsequent Securities and Exchange Commission filing for public review.